KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Cost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitReceivables - NetReceivables - Other
Ratios

Aurora Cannabis (ACB) Cost of Revenue (2017 - 2025)

Aurora Cannabis has reported Cost of Revenue over the past 9 years, most recently at $34.4 million for Q4 2025.

  • Quarterly Cost of Revenue rose 7.2% to $34.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $162.9 million through Dec 2025, up 37.27% year-over-year, with the annual reading at $108.5 million for FY2025, 6.02% up from the prior year.
  • Cost of Revenue was $34.4 million for Q4 2025 at Aurora Cannabis, down from $39.8 million in the prior quarter.
  • Over five years, Cost of Revenue peaked at $100.8 million in Q1 2021 and troughed at -$179.3 million in Q2 2021.
  • The 5-year median for Cost of Revenue is $35.9 million (2022), against an average of $28.5 million.
  • The largest YoY upside for Cost of Revenue was 209.64% in 2021 against a maximum downside of 182.04% in 2021.
  • A 5-year view of Cost of Revenue shows it stood at $56.8 million in 2021, then dropped by 25.64% to $42.3 million in 2022, then dropped by 23.91% to $32.2 million in 2023, then decreased by 0.13% to $32.1 million in 2024, then increased by 7.2% to $34.4 million in 2025.
  • Per Business Quant, the three most recent readings for ACB's Cost of Revenue are $34.4 million (Q4 2025), $39.8 million (Q3 2025), and $44.8 million (Q2 2025).